Full-Time

Director Core Labeling Strategy

Posted on 8/21/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

Compensation Overview

$112k - $236k/yr

Washington, DC, USA

In Person

Bachelor's, Master's, PharmD, PhD

Category
Biology & Biotech (1)
Required Skills
Risk Management

Get referred to Viatris

See people who can refer or advise you

Requirements
  • A minimum of a Bachelor's degree (or equivalent) in Science, Medicine, Pharmacy, or another related field with 10 years of regulatory experience, including significant experience in global labelling strategy and development.
  • Demonstrated experience in labelling development, including development and maintenance of global core labelling such as Company Core Data Sheets and major-market labelling such as US Prescribing Information and EU Summary of Product Characteristics.
  • Regulatory experience including in-depth global labelling knowledge across development and lifecycle management, including Product Labeling Team and Global Labelling Committee governance processes and EU and US regulatory labelling requirements.
  • Familiarity with competitive labelling assessments and experience in Target Product Labelling development to support regulatory strategy.
  • Experience in developing first-submission labelling for innovative products in major regulatory markets such as the United States and European Union.
  • Prior leadership experience with direct reports and demonstrated ability to lead and develop others.
  • Ability to read and interpret comprehensive and intricate research documents; write scientific reports and technical correspondence; work with executives; communicate abstract concepts; and present to a high level of the organization and groups outside the organization.
  • Ability to solve problems with a variety of concrete variables through semi-standardized solutions requiring ingenuity and analysis, and to draw inferences and follow prescribed and detailed procedures to solve moderately complex problems.
  • Highly developed interpersonal, presentation, and communication skills, including the ability to provide innovative labelling recommendations that meet corporate goals while maintaining compliance with relevant laws and regulations and to influence effectively in a matrixed, cross-functional team environment.
  • Ability to perform job functions in accordance with applicable Standard Operating Procedures, federal and state laws, Occupational Safety and Health Administration guidelines, health authority regulations, and departmental processes.
Responsibilities
  • Provide regulatory labelling leadership, governance, and expertise so that product information texts for existing and new products are developed, maintained, and implemented globally in compliance with applicable regulatory requirements.
  • Create, develop, and maintain compliant Core Labelling documents, including Company Core Data Sheets and associated patient information, and oversee Global Advertising, Promotional, and Medical Marketing review and approval.
  • Contribute to strategic labelling development across the product lifecycle, including supporting early development programmes through Target Product Labelling, competitive labelling analyses, and regulatory precedent assessments for global regulatory strategy and major submissions.
  • Manage the global labelling process and labelling development across the assigned portfolio.
  • Lead preparation, review, and approval of global and territorial labelling documentation based on clinical and non-clinical dossiers to support regulatory filings with international regulatory agencies.
  • Drive labelling strategy in partnership with Global Regulatory for Company Core Data Sheets, US Prescribing Information, abbreviated Prescribing Information, and group-managed EU Summary of Product Characteristics.
  • Lead development and maintenance of Target Product Labelling to guide clinical development strategy, regulatory positioning, and cross-functional alignment.
  • Partner with project leads, the regulatory matrix, the aligned Regulatory Strategist, and stakeholder teams to lead labelling activities across development and lifecycle management.
  • Lead labelling updates and development by evaluating the data and principles supporting labelling statements for clinical relevance and regulatory acceptance.
  • Control global labelling compliance by reconciling labelling deviations with the Company Core Position, assessing change requests, driving responses to Health Authorities and other requesting parties, and approving final outcomes.
  • Chair cross-functional Product Labeling Teams, identify and engage subject-matter experts, and collaborate with medical, clinical, product safety, risk management, and clinical safety teams to ensure product information content is scientifically accurate, validated, and aligned with safety and clinical requirements.
  • Initiate and manage escalation to the Global Labelling Committee when agreement cannot be reached on labelling issues.
  • Monitor competitor labels, external labelling trends, and agency requirements to inform labelling strategy and support product differentiation.
  • Negotiate resolutions of complex regulatory and scientific issues, manage multiple projects simultaneously, and apply judgment to solve complex problems.
  • Review and approve promotional materials against Company Core Data Sheets and relevant codes of conduct, and advise on competitor and existing company labelling documents.
  • Review, advise on, and approve documents from Clinical Development, Medical Affairs, Pharmacovigilance, and other scientific functions, including Investigator Brochures, clinical study protocols, clinical study reports, periodic reports, risk management plans, and Core Value Dossiers.
  • Influence interpretation of emerging regulatory guidelines and proposed regulations affecting labelling strategy.
  • Manage, lead, direct, and supervise direct reports, including recruitment, coaching, performance management, and development within the Labelling team, and contribute to leadership of the Global Labelling Organization.
  • Counsel project teams and participate in Regulatory team meetings, representing Labelling Strategy as appropriate.
  • Represent the company in industry groups and at European Medicines Agency or Food and Drug Administration-sponsored events when appropriate.
  • Perform other labelling duties as assigned.
Desired Qualifications
  • Demonstrated experience developing first-cycle or initial-submission labelling for innovative products in major regulatory markets, such as New Drug Application, Biologics License Application, or Marketing Authorisation Application submissions.
  • Experience in strategic labelling activities such as Target Product Labelling development, competitive label benchmarking, and regulatory submission support.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
  • Gross leverage fell to 2.9x after repaying roughly $900 million debt.
  • Fast-acting meloxicam has a December 27, 2026 FDA action date, supporting pipeline value.

What critics are saying

  • Tyvarya rights sale to Harrow shrinks growth assets and signals portfolio pruning.
  • Merck sitagliptin litigation still threatens U.S. generic launches through 2026 appeals.
  • EpiPen settlements keep Mylan-era pricing conduct alive, risking future antitrust liabilities.

What makes Viatris unique

  • Viatris spans branded, generic, and biosimilar medicines across 165 countries.
  • Greater China delivered 21% Q2 2026 growth through established brands and e-commerce.
  • FDA-approved Gwyn Lo and meloxicam add near-term proprietary launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.

Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.

PR Newswire
Aug 6th, 2026
Viatris reports Q2 revenues of $3.8B, up 5%, raises 2026 guidance despite $119M loss

Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.

Yahoo Finance
Aug 2nd, 2026
Viatris wins FDA approval for Gwyn Lo contraceptive patch

Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.

TipRanks
Jul 1st, 2026
Viatris secures $260M term loan facility to refinance debt and support operations

Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.